Attachment A11

DUCOM Letter About Type of Consent

NIDA'S STUDY OF SUBSTANCE ABUSE DOC.COM MODULE PROJECT

April 2011

Office of Regulatory Research Compliance

APPROVAL NOTICE WITHOUT CONSENT

TO:

Barbara A. Schindler, M.D.

SOM Faculty Group Practice / Total Psychiatry

Eranle Tuinehen

Mailstop: QL

FROM:

Francis Linnehan , Ph.D. , Chair Institutional Review Board (IRB #3) Drexel University College of Medicine

1601 Cherry Street, Suite 10444, 3-Parkway, Philadelphia, Pa 19102

Tel: 215-255-7864 Fax: 215-255-7874

SUBJECT: Evaluation of NIDA Substance Abuse doc.com Module

SPONSOR: Internal

PROJECT No: 1044381, PROTOCOL No: 19630, ACTION No: 57291 Type:

New Period: 1 Seq: 1, DETAIL No: 273524

CURRENT APPROVAL PERIOD: 03/31/2011, EXPIRES: 03/29/2012

RE:

03/31/11 – According to 45 CRF 46.110, this study is Approved Expedited

Category 7.

Please Note: The Drexel University IRB has a reliance on the IRB of the University of Pennsylvania. The protocol has been approved by University of Pennsylvania IRB, along with the consent form to be used. All continuing reviews should be handled by University of Pennsylvania with copies of all correspondence being submitted to Drexel University.

Date:

4/6/2011

On behalf of the Committee, I am pleased to inform you that the subject protocol has been reviewed and approved for the period indicated above. We operate under many Government requirements. As a result, this approval is granted with the following understandings:

 If this is a sponsored project, then the study may not be activated until the Contract is fully executed by the Clinical Research Group. If this is not a sponsored study (designated "internal"), the costs of the project must be identified and a cost center designated. Please call 215-255-7857 if you have any questions regarding these procedures.

1601 Cherry Street, 3 Parkway Buildiing, Suite 10444 • Philadelphia, PA 19102 • Phone 215-255-7857 • Fax 215-255-7874 www.research.drexel.edu • www.drexelmed.edu

- 2. You must advise the IRB of the activation date. "Activation" for the purposes of this notice is the enrollment of the first human subject or the performance of the first experimental procedure on or after the above approval date. Please use the ACTIVATION NOTICE for this purpose.
- 3. Any change to the protocol must be submitted in writing and approved by the IRB in advance.
- 4. Any adverse reaction must be reported to the IRB as soon as it occurs.
- 5. Should the IRB decide to monitor your project directly, please cooperate fully. Failure to do so may result in withdrawal of this approval and notification to the sponsor and/or Federal agencies. Specific information regarding monitoring appears in GUIDELINES FOR BIOMEDICAL AND BEHAVIORAL RESEARCH INVOLVING HUMAN SUBJECTS, and GUIDELINES FOR NON-MEDICAL obtainable through this office or the website http://research.drexel.edu.
- 6. Whether or not this protocol is activated, the IRB will conduct Continuing Review at least annually. Should you fail to respond to this Federally-required continuing review and progress report, the project may become ineligible for re-approval and the IRB may choose not to consider other projects for approval.
- 7. A final progress report must be submitted to the IRB in format similar to that of a periodic report.

The IRB welcomes your research project into the list of approved protocols. Your compliance with the above conditions will help to protect the continuation of all research activity at the University. With your project and others like it, we look forward to additions to knowledge of human health and benefits to science, our patients, and society.

cc: IRB Chair, Dept Chair, Tenet, Drexel

MEMORANDUM Institutional Review Board (IRB #3)

ACTIVATION NOTICE

TO:	Institutional Review Board (IRB #3) 1601 Cherry Street, Suite 10444, 3-Parkway, Philadelphia, Pa 19102 Tel: 215-255-7864 Fax: 215-255-7874
FROM:	Barbara A. Schindler , M.D. SOM Faculty Group Practice / Total Psychiatry
SUBJECT:	ACTIVATION OF HUMAN RESEARCH PROTOCOL ENTITLED: Evaluation of NIDA Substance Abuse doc.com Module PROJECT No: 1044381, PROTOCOL No: 19630, ACTION No: 57291 Type: New Period: 1 Seq: 1, DETAIL No: 273524 DATE OF APPROVAL: 03/31/2011, EXPIRES: 03/29/2012
Date:	4/6/2011
This is to inform the Continuing Review	ne IRB that the subject protocol was activated* on $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $
[]Yes []No	I have a copy of the University's Human Subjects Guidelines and Federal Wide Assurance (FWA) to the OHRP, as required in 45 CFR Part 46.
on the Office of R There are two set You must have a To download a co 1. Go to http 2. Click "Me 3. Under "G	uidelines for Biomedical and Behavioral Research for the protection of human subjects have been posted esearch website. s of Guidelines - one each for Medical and Non-Medical Research. hard copy and read these Guidelines to make sure that these Guidlines are met. by of the University Guidlines, follow the below instructions: b://research.drexel.edu bdical IRB" or "Non-Medical IRB" in Quick Links to to", click "Medical IRB" or "Non-Medical IRB Guidelines" beep a copy of the University Guidelines in your office.
(Signed) Schindle	er, Barbara A.

^{* &}quot;Activated" means that the first new human subject was accrued, or an experimental procedure was performed, or records were reviewed under this protocol on or after the date of last approval: 03/31/2011.

Accordingly, this notice must be sent to the IRB ONLY for the FIRST such accrual since that date.